Navigation Links
Halozyme Secures Additional $20 Million Term Loan
Date:1/6/2014

ing, please visit our corporate website at www.halozyme.com and follow us on Twitter @HALOTherapeutic.

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the use of cash from its additional term loan) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2013.

Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
310-633-9434
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics, Infinity, and PTC Therapeutics
2. Halozyme Therapeutics Announces Executive Transitions
3. Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
4. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
5. Halozyme to Host Third Quarter 2013 Financial Results Conference Call
6. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
7. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
8. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
9. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
10. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
11. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... SPRINGDALE, Ark. , Sept. 1, 2015 NOWDiagnostics Inc., ... completed its acquisition of ZBx Corporation of Canada ... to its vision of a world where people have ... NOWDiagnostics manufactures and sells a line of unique blood-based ... simple-to-use, highly accurate tests for a variety of ailments ...
(Date:9/1/2015)... 1, 2015 UT Southwestern Medical Center President ... members joined U.S. Representatives Michael C. Burgess , ... discussion on the 21 st Century Cures Act, ... considered by the United States ... Academy of Sciences members, department chairs, center directors, and ...
(Date:9/1/2015)... Sept. 1, 2015  Results from an interim analysis ... that 5g of idarucizumab enabled emergency surgery to ... treated with dabigatran (Pradaxa ® dabigatran etexilate ... effect of dabigatran enabled patients to be urgently ... of 1.7 hours between administration of idarucizumab and ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9
... in wake of AHA-presented data , ... a clinical trial suggesting rosuvastatin may lower the cardiovascular risk ... statin use in older adults, according to a national poll ... the online poll conducted by medical news site MedPage Today ...
... FRANCISCO, Calif., Nov. 25 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... on,innovative oncology therapies, announced today that it will ... in order to allow,the Company to focus its ... product candidate, and to support the initial commercialization ...
Cached Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3
(Date:9/1/2015)... Miami, FL (PRWEB) , ... September 01, 2015 ... ... Food and Drug Administration (FDA) for the treatment of androgenic alopecia in adults, ... the brand new laser therapy cap, while also demonstrating its safety when used ...
(Date:9/1/2015)... ... September 01, 2015 , ... According to a ... with type 2 diabetes that participated in a three year study about weight loss ... the line if they elected weight loss surgery at the onset of the trial. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... managed, stress created from everyday life changes can lead to very serious, life-altering ... support for coping with stress. Herbal supplement manufacturer MediHerb has coupled ...
(Date:9/1/2015)... ... ... Philanthropic giving in the U.S. has been stuck at 2% GDP since the ... today by Camber Collective, goes to the root of this problem and provides a ... new philanthropic giving and shift $25B that’s already being donated, according to the report. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... cure and prevent different malignancies. Some options for cancer treatment are available ... to which distinctive approach is necessary for effective treatment. Several molecules have ...
Breaking Medicine News(10 mins):Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3
... Ill., Feb. 29 Landauer, Inc. (NYSE:,LDR) announced today ... dividend of $0.50 per share for the second quarter ... 4, 2008, to shareholders of record,on March 14, 2008., ... of analytical services to determine,occupational and environmental radiation exposure. ...
... Genoptix, Inc.,(Nasdaq: GXDX ), today announced the ... by certain existing stockholders to,the public at the price ... proceeds from the sale. The offer is expected to ... made through an underwriting syndicate led by,Lehman Brothers, Inc. ...
... Xing,Mobile Communication Co., Ltd. (,Qiao Xing Mobile, or ,the ... manufacturers of mobile,handsets through its subsidiary CEC Telecom Co., ... cardiograph mobile handset., The C7000A has the ... be able to perform a basic ...
... respiratory diseases like chronic bronchitis, but genes also play ... in Sweden, who studied more than 40,000 Swedish twins ... genes each play a role ion the development of ... known genetic component and smoking is a primary risk ...
... TULSA, Okla., Feb. 28 Presidential campaign fever is,running ... can,t hold a,candle to the presidential star power that ... Saturday night, March 1st, when they host the 16th,President ... Mr. Lincoln will be addressing Tulsa,s top doctors ...
... blood thinner continues , , THURSDAY, Feb. 28 (HealthDay News) ... center of recent problems with its blood thinner heparin, ... vials of the drug as well as single-dose vials. ... Hep-Lock heparin flush products, which contain a small amount ...
Cached Medicine News:Health News:Genoptix Announces Pricing of Secondary Public Offering 2Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 2Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 3Health News:Genetic factors in smoking also increase risk of chronic bronchitis 2Health News:Baxter Recalls Rest of Heparin Products 2Health News:Baxter Recalls Rest of Heparin Products 3
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
Medicine Products: